Chronic kidney disease (CKD) — staging & conservative (kidney-protective) management
Bedside summary
eGFR <60 mL/min/1.73m2 and/or markers of kidney damage (albuminuria ACR >=3 mg/mmol, haematuria, structural/pathological abnormality) persisting >=3 months. Staged by cause + GFR category (G1 >=90, G2 60-89, G3a 45-59, G3b 30-44, G4 15-29, G5 <15) + albuminuria category (A1 <3, A2 3-30, A3 >30 mg/mmol) — the KDIGO 'GFR/ACR' heat map grades risk of progression, CV death and kidney failure. Conservative management = slow progression (BP, RAS blockade, SGLT2i), treat complications (anaemia, CKD-MBD, acidosis, hyperkalaemia) and reduce CV risk.
Red flags
- Rapid eGFR decline (>5 mL/min/yr) or active urinary sediment (dysmorphic RBCs/casts) — suspect GN, urgent nephrology
- Nephrotic-range proteinuria (ACR >220 mg/mmol / PCR >300) or systemic features (rash, haemoptysis, arthralgia) — biopsy-level urgency
- Resistant hyperkalaemia or acidosis, uraemic encephalopathy/pericarditis, refractory fluid overload — RRT assessment
- Hypercalcaemia + anaemia + bone pain — exclude myeloma
- Bilateral small kidneys with anuria or hydronephrosis — obstruction needing decompression
Assessment
Differential diagnosis
- Acute kidney injury (normal-size kidneys, no anaemia/renal osteodystrophy, recent rise) — vs CKD (small echogenic kidneys, anaemia, hyperphosphataemia)
- Acute-on-chronic kidney disease
- Reversible drivers mimicking progression: hypovolaemia, NSAIDs/ACEi, obstruction, contrast
- Isolated low eGFR from reduced muscle mass (overestimates true impairment)
- Glomerular disease requiring biopsy (nephrotic-range proteinuria, active sediment, rapid decline)
Investigations
- U&E, creatinine + eGFR (CKD-EPI 2021, race-free); trend vs old results to confirm chronicity
- Urine ACR (first-morning) and urine dip/microscopy (haematuria, casts)
- FBC (normocytic anaemia), ferritin/transferrin saturation
- Bone profile: calcium, phosphate, PTH, vitamin D (CKD-MBD)
- Venous bicarbonate (metabolic acidosis), potassium
- HbA1c, lipids; renal USS (size, symmetry, obstruction, cysts, corticomedullary differentiation)
- Screen for cause where indicated: immunoglobulins/serum free light chains + urine Bence Jones, ANA/ANCA/anti-GBM/complement, HBV/HCV/HIV, PLA2R
Management
- Confirm chronicity (>=3 months of reduced eGFR or damage) and exclude reversible/AKI component before labelling
- Identify and treat the cause; stop nephrotoxins (NSAIDs, aminoglycosides); dose-adjust renally cleared drugs
- BP target <120 mmHg systolic (standardised office measurement) where tolerated; first-line ACEi or ARB (not both together) titrated to max tolerated dose if ACR >=3 mg/mmol or diabetes
- Start an SGLT2 inhibitor for eGFR >=20 with ACR >=20-22 mg/mmol (~>=200 mg/g) or type 2 diabetes with CKD, or heart failure — continue even as eGFR falls below 20 unless intolerant/dialysis (KDIGO 2024)
- Add finerenone in type 2 diabetic CKD with persistent albuminuria despite max RAS blockade if K+ <=4.8 and eGFR >=25 [verify local dose]
- Treat acidosis (aim bicarbonate >=22), hyperkalaemia, anaemia (iron then ESA when Hb <100 g/L after iron repletion), and CKD-MBD (phosphate binders, control PTH)
- Lifestyle: salt <5 g/day, moderate protein ~0.8 g/kg/day (avoid high-protein diets), smoking cessation, weight/exercise; 'sick-day rules' — withhold ACEi/ARB, SGLT2i, diuretics, metformin, NSAIDs during dehydrating illness
- Statin (atorvastatin) for CV risk reduction in essentially all CKD; refer to nephrology if eGFR <30, ACR >70 mg/mmol, rapid decline (>5 mL/min/yr), refractory complications, or suspected genetic/inflammatory cause; plan access/transplant work-up as G4-5 approaches
Drugs & doses
Disposition
Complications & pitfalls
- Progression to kidney failure (G5) requiring dialysis/transplant
- Accelerated cardiovascular disease (leading cause of death)
- Renal anaemia; CKD-mineral bone disorder (secondary hyperparathyroidism, vascular calcification, fractures)
- Hyperkalaemia and metabolic acidosis
- Volume overload, uncontrolled hypertension, drug accumulation/toxicity
Exam pearls
- KDIGO 2024 CKD guideline: SGLT2i is now foundational (diabetic and non-diabetic albuminuric CKD) alongside RAS blockade, statin and BP control — the '4 pillars' of kidney protection.
- An eGFR drop up to ~30% and a small K+ rise after starting ACEi/ARB or SGLT2i is expected and not a reason to stop — recheck and continue.
- Give every CKD patient written 'sick-day rules' and a nephrotoxin-avoidance list; most 'progression' presenting acutely is superimposed reversible AKI.
- Use the ACR, not just eGFR, to stratify risk and refer — a G3a/A3 patient outranks a G3b/A1 patient for renal and CV risk.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.